Amyloidosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Amyloidosis Pipeline Drugs Market Overview
Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of an abnormal protein called the light chain and its subsequent deposition in the body. It may also occur because of dialysis. Symptoms include fatigue, chest pain, swelling, and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.
The Amyloidosis drugs in development market research report provide comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects.
Key Targets in the Amyloidosis Pipeline Products Market
The key targets in the Amyloidosis pipeline products market are Transthyretin, Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide, Alpha Synuclein, Amyloid Beta A4 Protein, Interleukin 1 Beta, Microtubule Associated Protein Tau, B Cell Lymphoma 2, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, 20s Proteasome, and others.
Amyloidosis Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Amyloidosis Pipeline Products Market
The key mechanisms of action in the Amyloidosis pipeline products market are Transthyretin Inhibitor, Cytotoxic To Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide Inhibitor, Transthyretin Activator, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Interleukin 1 Beta Inhibitor, Microtubule Associated Protein Tau Inhibitor, B Cell Lymphoma 2 Inhibitor, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and others.
Amyloidosis Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Amyloidosis Pipeline Products Market
The key routes of administration in the Amyloidosis pipeline products market are intravenous, subcutaneous, oral, parenteral, and topical.
Amyloidosis Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Amyloidosis Pipeline Products Market
The key molecule types in the Amyloidosis pipeline products market are small molecule, monoclonal antibody, fusion protein, antisense RNAi oligonucleotide, gene therapy, Antisense Oligonucleotide, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, recombinant peptide, antibody, and others.
Amyloidosis Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Amyloidosis Pipeline Products Market
Some of the major companies in the Amyloidosis pipeline products market are Alnylam Pharmaceuticals Inc, Akcea Therapeutics Inc, Attralus Inc, Johnson & Johnson, Alexion Pharmaceuticals Inc, Autotac Bio Inc, BridgeBio Pharma Inc, BSIM Therapeutics SA, Millennium Pharmaceuticals Inc, and Proclara Biosciences Inc.
Amyloidosis Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
| Key targets | Transthyretin Inhibitor, Cytotoxic To Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide Inhibitor, Transthyretin Activator, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Interleukin 1 Beta Inhibitor, Microtubule Associated Protein Tau Inhibitor, B Cell Lymphoma 2 Inhibitor, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and Others |
| Key mechanism of action | Transthyretin Inhibitor, Cytotoxic To Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide Inhibitor, Transthyretin Activator, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Interleukin 1 Beta Inhibitor, Microtubule Associated Protein Tau Inhibitor, B Cell Lymphoma 2 Inhibitor, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and others |
| Key routes of administration | Intravenous, Subcutaneous, Oral, Parenteral, and Topical |
| Key molecule type | Small Molecule, Monoclonal Antibody, Fusion Protein, Antisense RNAi Oligonucleotide, Gene Therapy, Antisense Oligonucleotide, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Recombinant Peptide, Antibody, and Others |
| Major companies | Alnylam Pharmaceuticals Inc, Akcea Therapeutics Inc, Attralus Inc, Johnson & Johnson, Alexion Pharmaceuticals Inc, Autotac Bio Inc, BridgeBio Pharma Inc, BSIM Therapeutics SA, Millennium Pharmaceuticals Inc, and Proclara Biosciences Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AbbVie Inc
ADRx Inc
Akcea Therapeutics Inc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Amyl Therapeutics
Attralus Inc
Autotac Bio Inc
Auven Therapeutics Development Switzerland Sarl
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
Brooklyn ImmunoTherapeutics Inc
BSIM Therapeutics SA
Chugai Pharmaceutical Co Ltd
Corino Therapeutics Inc
Covalent Bioscience Inc
Dren Bio Inc
EUSA Pharma (UK) Ltd
GlaxoSmithKline Plc
Guangdong Yinzhu Pharmaceutical Technology Co Ltd
HaemaLogix Pty Ltd
IMMvention Therapeutix Inc
Johnson & Johnson
Karyopharm Therapeutics Inc
Mabpharm Ltd
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Novo Nordisk AS
Precision Biosciences Inc
Proclara Biosciences Inc
Prothena Corp Plc
R-Pharm
Regeneron Pharmaceuticals Inc
ResQ Biotech
Sanofi
Shanghai YaKe Biotechnology Co Ltd
SOLA Biosciences LLC
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Telix Pharmaceuticals Ltd
Vera Therapeutics Inc
Zentalis Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Amyloidosis pipeline products market?
The key targets in the Amyloidosis pipeline products market are Transthyretin, Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide, Alpha Synuclein, Amyloid Beta A4 Protein, Interleukin 1 Beta, Microtubule Associated Protein Tau, B Cell Lymphoma 2, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, 20s Proteasome, and others.
-
What are the key mechanisms of action in the Amyloidosis pipeline products market?
The key mechanisms of action in the Amyloidosis pipeline products market are Transthyretin Inhibitor, Cytotoxic To Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1, Amyloid Protein And Peptide Inhibitor, Transthyretin Activator, Alpha Synuclein Inhibitor, Amyloid Beta A4 Protein Inhibitor, Interleukin 1 Beta Inhibitor, Microtubule Associated Protein Tau Inhibitor, B Cell Lymphoma 2 Inhibitor, Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17, and others.
-
What are the key routes of administration in the Amyloidosis pipeline products market?
The key routes of administration in the Amyloidosis pipeline products market are intravenous, subcutaneous, oral, parenteral, and topical.
-
What are the key molecule types in the Amyloidosis pipeline products market?
The key molecule types in the Amyloidosis pipeline products market are small molecule, monoclonal antibody, fusion protein, antisense RNAi oligonucleotide, gene therapy, antisense oligonucleotide, gene-modified cell therapy, monoclonal antibody conjugated, recombinant peptide, antibody, and others.
-
Which are the major companies in the Amyloidosis pipeline products market?
Some of the major companies in the Amyloidosis pipeline products market are Alnylam Pharmaceuticals Inc, Akcea Therapeutics Inc, Attralus Inc, Johnson & Johnson, Alexion Pharmaceuticals Inc, Autotac Bio Inc, BridgeBio Pharma Inc, BSIM Therapeutics SA, Millennium Pharmaceuticals Inc, and Proclara Biosciences Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Metabolic Disorders reports